Patents Examined by Peter J. Reddig
  • Patent number: 10292979
    Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on genotyping and expression profiling of certain immunological genes and RAS mutation status in the subject.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: May 21, 2019
    Assignee: Kura Oncology, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Patent number: 10280224
    Abstract: Anti-PD-1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: May 7, 2019
    Assignee: Agency For Science, Technology and Research
    Inventors: Cheng-i Wang, Hsueh Ling Janice Oh, Siok Ping Yeo, Jianrong Lionel Low, Hwee Ching Tan
  • Patent number: 10273294
    Abstract: Described herein are compositions that include monoclonal antibodies that specifically bind Hsp90? and methods of using the same to treat HIF-1?-overexpressing cancer. In some embodiments, the cancers are breast cancer or lung cancer. The monoclonal antibodies bind the epitope TKPIWTRNP (SEQ ID NO: 1) in Hsp90? or VKHFSVEGQ (SEQ ID NO: 2) in Hsp90?.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: April 30, 2019
    Assignee: University of Southern California
    Inventors: Wei Li, David Woodley, Mei Chen, Divya Sahu, Hangming Dong, Mengchen Zou
  • Patent number: 10267801
    Abstract: This disclosure relates to a diagnostic/prognostic assay for prostate cancer and including kits used in said assay.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: April 23, 2019
    Inventor: Ronald Alfred Laskey
  • Patent number: 10253077
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: April 9, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Valentina Goldfinger, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10253086
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: April 9, 2019
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Hans Bitter, Jennifer Mary Bordeaux, Barbara Brannetti, Jennifer Brogdon, Naveen Kumar Dakappagari, Saar Gill, Steven Highfill, Lu Huang, Carl H. June, Ju Young Kim, Ming Lei, Na Li, Andreas Loew, Elena Orlando, Marco Ruella, Thai Tran, Jimin Zhang, Li Zhou
  • Patent number: 10254285
    Abstract: The invention provides methods for isolating large oncosomes and determining cancer metastasis based on the presence of large oncosomes and contents of the large oncosomes in a subject in need thereof. Also provided herein are methods for treating cancer metastasis by specifically targeting contents of the large oncosomes.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: April 9, 2019
    Assignee: Cedars-Sinai Medical Center
    Inventors: Dolores Di Vizio, Michael R. Freeman, Matteo Morello, Valentina R. Minciacchi
  • Patent number: 10238725
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: March 26, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Anita Wiebe, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10238724
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: March 26, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Anita Wiebe, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10241115
    Abstract: The present disclosure describes an IHC assay for detecting and quantifying spatially proximal pairs of PD-1-expressing cells (PD-1+ cells) and PD-Ligand-expressing cells (PD-L+ cells) in tumor tissue, and the use of the assay to generate proximity biomarkers that are predictive of which cancer patients are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods for testing tumor samples for the proximity biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: March 26, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Robert H. Pierce, Jennifer H. Yearley, Scott P. Turner, Belma Dogdas, Ansuman Bagchi
  • Patent number: 10238726
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: March 26, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Anita Wiebe, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10227409
    Abstract: Disclosed herein are chimeric antigen receptors (CAR) that can specifically recognize tumor-associated antigens (TAA) on multiple myeloma (MM) cells. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with MM that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: March 12, 2019
    Assignee: Ohio State Innovation Foundation
    Inventors: Jianhua Yu, Craig Hofmeister, Jianhong Chu
  • Patent number: 10220091
    Abstract: Methods for treating cancer using a combination of an inhibitor of the sonic hedgehog signaling pathway (e.g., LDE225) with radiation and a tumor antigen-specific monoclonal antibody (e.g., heat shock protein (HSP) glucose regulated protein of 94000 daltons (Grp94)-specific mAb W9, or chondroitin sulfate proteoglycan 4 (CSPG4)-targeted mAbs), or with a BRAF inhibitor, e.g., in BRAF inhibitor resistant cancers.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: March 5, 2019
    Assignee: The General Hospital Corporation
    Inventors: Francesco Sabbatino, Yangyang Wang, Xinhui Wang, Steven Isakoff, Cristina Ferrone, Joe Schwab, Soldano Ferrone
  • Patent number: 10208125
    Abstract: This disclosure provides anti-MUC1 binding agents (e.g., antibodies and chimeric antigen receptors) and methods of treatment, prophylaxis, detection, and diagnosis using the same.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: February 19, 2019
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, Bluefin BioMedicine, Inc.
    Inventors: Robert E. Schoen, Olivera J. Finn, Shuji Sato, Wan Cheung Cheung, Roberto D. Polakiewicz
  • Patent number: 10195272
    Abstract: A chimeric antigen receptor (CAR) contains a human Fc?RI? extracellular domain or a mutant Fc?RI? extracellular domain that has a reduced binding affinity for human IgE compared to wild type human Fc?RI? extracellular domain. The CAR further contains an intracellular signaling domain comprising at least one immunoreceptor-based activation motif (ITAM). The CAR may further comprise a costimulatory signaling domain, such as an intracellular domain of at least one of the costimulatory molecules 4-1BB, CD27, CD28, CD134 or ICOS. T cells transduced with vectors encoding the CAR are used in CAR-based adoptive T-cell therapy for targeting IgE-expressing B cells and treating IgE-mediated allergic diseases.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: February 5, 2019
    Assignee: The Nemours Foundation
    Inventor: Zhengyu Ma
  • Patent number: 10196422
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: February 5, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Hans-Georg Rammensee, Juliane Stickel, Daniel Kowalewski, Stefan Stevanovic, Simon Walz
  • Patent number: 10196608
    Abstract: The present invention pertains to engineered T-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered T-cells of the invention are designed to express both a Chimeric Antigen Receptor (CAR) directed against at least one antigen expressed at the surface of a malignant or infected cell, and a secreted inhibitor of regulatory T-cells (Treg). Preferably, such secreted inhibitor is a peptide inhibitor of forkhead/winged helix transcription factor 3 (FoxP3), a specific factor involved into the differentiation of T-cells into regulatory T-cells. The engineered T-cells of the invention direct their immune activity towards specific malignant or infected cells, while at the same time will prevent neighboring regulatory T-cells from modulating the immune response. The invention opens the way to standard and affordable adoptive immunotherapy strategies, especially for treating or preventing cancer, and bacterial or viral infections.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: February 5, 2019
    Assignee: CELLECTIS
    Inventors: Laurent Poirot, Philippe Duchateau
  • Patent number: 10189880
    Abstract: The technology relates in part to compositions and methods for inducing an immune response against a Bob1 antigen. Provided are methods for treating hyperproliferative diseases by inducing an immune response against a Bob1 antigen; the immune response may be induced using a Bob1 polypeptide fragment, or by specifically targeting Bob1-expressing cells using T cell receptors directed against Bob1.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: January 29, 2019
    Assignee: LEIDEN UNIVERSITY MEDICAL CENTER
    Inventors: Mirjam H. M. Heemskerk, J. H. Frederik Falkenburg
  • Patent number: 10191056
    Abstract: The present invention relates to a plurality of antigens that together form a panel of immunoreactive molecules suitable for identifying candidates for prostate cancer examination. Methods for identifying antibodies indicative of a pre-malignant or malignant prostate are disclosed. Further disclosed are kits that can be used to practice the above methods.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: January 29, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Douglas G. McNeel, Brett B. Maricque
  • Patent number: 10188714
    Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising mucin-1 (MUC1), as well as methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of mucin-1 (MUC1).
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: January 29, 2019
    Assignees: GlobeImmune, Inc., The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Alex Franzusoff, Zhimin Guo, Jeffrey Schlom, Kwong-Yok Tsang